Related Experiment Video

Updated: Aug 6, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

[Therapeutic effect and impact on cytokine production by methotrexate in rheumatoid arthritis]

Xiao-yun Sun1, Yin Su, Li-min Ren

  • 1Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.

Beijing Da Xue Xue Bao. Yi Xue Ban = Journal of Peking University. Health Sciences
|August 8, 2006
PubMed
Abstract

Insights

Methotrexate significantly improves rheumatoid arthritis symptoms and reduces joint damage. This treatment lowers pro-inflammatory cytokines like TNF-alpha and IL-6 while increasing anti-inflammatory IL-10.

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and damage.
  • Cytokine dysregulation, particularly elevated pro-inflammatory cytokines, plays a key role in RA pathogenesis.

Purpose of the Study:

  • To evaluate the clinical efficacy of methotrexate (MTX) in RA patients.
  • To investigate the impact of MTX monotherapy on the production of key pro-inflammatory and anti-inflammatory cytokines.

Main Methods:

  • Thirty RA patients received oral methotrexate (15 mg/week) for 24 weeks.
  • Clinical response was assessed using American College of Rheumatology (ACR) criteria at multiple time points.
  • Serum levels of TNF-alpha, INF-gamma, IL-1beta, IL-6, and IL-10 were measured before and after treatment.

Main Results:

  • Methotrexate treatment led to significant clinical improvement, with 70% achieving ACR20, 30% ACR50, and 10% ACR70 response.
  • Pro-inflammatory cytokines (IL-6, TNF-alpha, INF-gamma) were significantly decreased post-MTX therapy.
  • The anti-inflammatory cytokine IL-10 showed a significant increase after methotrexate treatment.

Conclusions:

  • Methotrexate is an effective monotherapy for managing rheumatoid arthritis symptoms and potentially mitigating joint damage.
  • MTX therapy modulates the cytokine profile in RA patients, reducing pro-inflammatory mediators and enhancing anti-inflammatory responses.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...